RussianPatents.com

Method of obtaining pharmaceutical composition for oral introduction possessing improved bioaccessibility of biologically active effective medicinal substance, and pharmaceutical composition obtained by said method. RU patent 2370268.

FIELD: medicine.

SUBSTANCE: method of obtaining tablets containing crystalline-form-free alprazolam, includes at preliminary stage of granulation operation obtaining alprazolam solution in pharmacologically acceptable solvent together with crystallisation-inhibiting agent, formed by mixture of binding substance and from 20 to 60% wt of total amount of lubricating substance, impregnation with obtained solution of mixture of diluent and 25% reticular carboxymethylcellulose as disintegrating agent until homogeneous granulated mass is obtained and grinding of obtained granulated mass, preliminarily dried, until grinded granulometrically homogeneous mass is obtained. At the second stage of granulation operation, 100% of remaining lubricating agent and remaining reticular carboxymethylcellulose and aromatising additives are added to dried and grinded mass, obtained at preliminary stage of granulation operation; aromatised mass is finally mixed and pressed. Non-crystalline state of alprazolam improves its solvability and bioaccessibility.

EFFECT: alprazolam tablets have smaller size than traditional tablets, and disintegration time less than 1 minute, preferably, less than 30 seconds.

11 cl, 7 dwg, 3 tbl, 3 ex

IPC classes for russian patent Method of obtaining pharmaceutical composition for oral introduction possessing improved bioaccessibility of biologically active effective medicinal substance, and pharmaceutical composition obtained by said method. RU patent 2370268. (RU 2370268):

A61P25/24 - Antidepressants

A61P25/22 - Anxiolytics

A61K9/20 - Pills, lozenges or tablets

A61K47/38 - Cellulose; Derivatives thereof

A61K47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

A61K31/5517 -

A61K31/4196 -

A61J3/10 - into the form of compressed tablets (tablet presses B30B0011000000)

Another patents in same IPC classes:

Dihydrotetrabenazenes and pharmaceutical compositions containing them / 2365590
Invention relates to novel 3,11b-cys-dihydrotetrabenazene of general formula (1) or to its antipode . Invention also relates to composition, to pharmaceutical composition, to application of 3,11b-cys-dihydrotetrabenazene, to method of obtaining 3,11b-cys-dihydrotetrabenazene by i. 1, to compounds of formula (II), (III), as well as to ester of Mosher's acid and 3,11b-cys-dihydrotetrabenazene.

Antidepressive agent / 2363480
Application of 3% catolyte of a sodium chloride solution with ORP parametres minus 450-600 mV, pH - 8.2-9.5 for treatment of depressions is offered. It is shown in experiments and in clinical practice that 3% catolyte of a sodium chloride solution with ORP parametres minus 450-600 mV, pH - 8.2-9.5 possesses potentiating activity in relation to antidepressive preparations, besides, has own antidepressive effect.

Anticonvulsant medical product / 2361591
Invention concerns medicine and pharmacy area, in particular, to the medical products used for treatment of epilepsy and neuropathic pain. The agent contains carbamazepine and thyotriazoline in a mass parity 1: (0.25-2.5) in quality of an active base according to the invention. The agent possesses anticonvulsant, neuroprotective, nootropic, analgetic, antidepressive, actoprotective and antioxidatic action. Use of the combined agent under the invention allows to raise efficiency of treatment of the specified diseases in comparison with use of carbamazepine and thyotriazoline separately and to lower implication of toxic action of an agent at treatment.

Prevention technique of postoperative nausea and vomiting and reduction of postoperative depression period in children underwent ophthalmosurgical procedures / 2360674
Invention refers to medicine, namely to surgical ophthalmology and anaesthesiology and can be used as a prevention technique of postoperative nausea and vomiting, and also within postoperative depression. It is ensured as follows. Premedication is combined with introduction of nonsteroid antiinflammatory agent in an age-specific dose. Premedication then does not include introduction of Dimedrol, Droperidol and Metaclopramide.

Derivatives of carbostyril and stabilisers of mood for treatment of disorders of mood / 2359675
Pharmaceutical composition under the given invention contains a bond, in particular carbostyril derivative which is the stabiliser of a dopamine-thrombotonin system, and the mood stabiliser in a pharmaceutically comprehensible carrier. The bond, in particular carbostyril derivative, can represent aripiprazole or its metabolite. The mood stabiliser, without restriction, can include lithium, valporic acid, Sodium Divalproex, Carbamazepine, Oscarbamazepine, Zonisamide, Lamotrigine, Topiramat, Gabapentin, Levetiracetam or Clonazepamum. The named compositions are used for treatment of patients with mood disorders, especially bipolar disorder with psychotic implications and without them, the maniacal or admixed episodes.

Pyrrolopyrimidinone derivatives / 2358975
Present invention relates to new pyrrolopyrimidinone derivatives with formula (I) and their pharmaceutically used salts, with inhibition properties towards GSK-3, as well as to intermediate compounds with formula (Ic). In compounds with formula (I) and formula (Ic)

Derivatives of imidazo-pyridine, with affinity to melanocortin receptor / 2358974
Described are new derivatives of imidazo-pyridine with general formula I in racemic, enantiomeric form or in combination of these forms, and their pharmaceutically used salts. Radicals R1-R4 are described in the description.

Carbostyril derivatives and serotonin reuptake inhibitors for phrenopathy treatment / 2356554
According to the invention pharmaceutical composition contains carbostyril derivative and serotonin reuptake inhibitor in pharmaceutically acceptable carrier. Carbostyril derivative is aripiprazole. Serotonin reuptake inhibitor can include fluoxetine, duloxetine, venlafaxine, milnaciprane, cytalopram, fluvoxamine, paroxetine, sertraline or escitalopram. According to the invention, the pharmaceutical composition can be used for treatment of phrenopathy patients, particularly suffering from depression or major depressive disorder.

Comt inhibitors / 2354655
Invention refers to new compounds of formula I where R1 stands for H, CN, halogen, -COR2, -S(O)xR2, C1-C12alkyl, C2-C12alkenyl, C3-C8dicloalkyl, aryl group, heteroaryl group standing for 5- or 6-merous aromatic mono- or bicyclic heterocyclic group with 1-2 heteroatoms, chosen of N or S, C3-C8cycloalkyl-(C1-C3)alkyl or group aril-(C1-C3)alkyl; alkyl, alkenyl, cycloalkyl, aryl and heteroaryl groups can be optionally substituted with halogen, C1-C6alkyl, group-COR2; R2 stands for -N(R3,R3'), C1-C6alkyl, C3-C8cycloalkyl, aryl, heteroaryl which stands for 5- or 6-merous aromatic mono- or bicyclic heterocyclic group with 1-2 heteroatoms chosen of N, C3-C8cycloalkyl-(C1-C3) alkyl or aril-(C1-C3)alkyl; C1-C6alkyl, C3-C8cycloalkyl, aryl, heteroaryl can be optionally substituted with halogen, C1-C6alkyl; R3 and R3' independently stands for hydrogen or (C1-C3)alkyl; x stands for 0, 1 or 2; and also to their esters, hydrolyzed in physiological environment, and to their pharmaceutically acceptable salts. The invention also concerns a medical product.

Method of treatment or prevention of central nervous system diseases by means of compounds possessing selectivity with respect to alpha-3-subunit of benzodiazepine receptor / 2354377
Inventions relate to medicine, in particular to psychiatry and can be used for treatment or prevention of anxiety state or anxiety state episode. Pharmaceutical composition includes efficient amount of ELB 139 (1-(4-chlorphenyl)-4-pyperidinoimidazolin-2-on) or 1-(4-methoxyphenyl)-4-pyperidinoimidazolin-2-on, and method includes introduction to patient of efficient amount of ELB 139 (1-(4-chlorphenyl)-4-pyperidinoimidazolin-2-one) or 1-(4-methoxyphenyl)-4-pyperidino imidazolin-2-one.

Imidazole iii derivatives / 2360911
In general formula I R1 stands for haloid, lower alkyl; R2 stands for lower alkyl or C3-C6-cycloalkyl; R3 stands for lower alkyl, C3-C6-cycloalkyl, -(CH2)n-C3-C6-cycloalkyl, (CH2)n-CN or -(CH2)n-O-(lower)alkyl, (lower)alkoxyaryl, Fn-R5, where R5 is lower alkyl or lower alkenyl; n takes values 1, 2 or 3; R4 is hydrogen or CH2R5, where R5 is hydrogen, C1-C6-alkyl, C3-C12-cycloalkyl; as well as its pharmaceutically acceptable salts. Invention also relates to methods of obtaining formula I compounds, medication based on formula I compound and its application.

Oral gindarine medicine and production method / 2360675
Invention refers to chemical-pharmaceutical industry and medicine, namely to oral gindarine medicine characterised as a tranquilizer. Said medicine contains gindarine hydrochloride as an active material and auxiliary components and represents a solid gelatinous capsule. Gindarine is included as a compound of the mass filling capsules as mixed powders of gindarine and auxiliary components or as a granulated material. As the auxiliary components, the medicine contains bulking agent either alone, or combined with a disintegrant or antifriction material or with their mixture. There is also provided method of production of specified oral medicine.

Glycosaminoglycans for emotional insanity treatment / 2353371
There is disclosed application of glycosaminoglycan fraction of apparent molecular weight 2400 (±200)D depolymerised from glycosaminoglycan chosen from heparan sulphate and heparin for preparation of pharmaceutical compositions for treating the emotional insanities chosen from depressive disorder, qualm, anxiety neurosis, agitation, mental confusion. Additionally there is disclosed emotional insanity treatment method with no excitory influence depressing effect on central nervous system.

Application of carbamazepine derivatives for treating excitation in patients suffering from dementia / 2351338
Invention relates to field of medicine and pharmacology and concerns application of carbamazepine derivatives of formula (1) for treating excitation in patients, method of excitation treatment, pharmacologic composition for excitation treatment, combination of formula (1) compound with nootropic agent for excitation treatment, application of combination for preparation of medication for treating excitation and industrial packing.

Method of treatment of neurosis of obsessional conditions / 2350331
Invention concerns medicine, namely to psychiatry, and can be used at treatment of patients with a neurosis of obsessional conditions. For this purpose within 20 days pharmacotherapy is performed, including Diazepamum introduction, Mexidol and Tymogene. Thus Tymogene is administered intramusculary in a dose of 0.1-0.125 mg once in two days in amount of 10 injections. Simultaneously with pharmacotherapy within the first 15 days hyperbaric oxygenation is performed.

Method of hysterical neurosis treatment / 2350330
Invention concerns medicine, namely psychiatry, and can be used at treatment of patients with a hysterical neurosis. For this purpose pharmacotherapy is performed within 20 days including administration of 0.5% solution of Diazepamum intramusculary, 2-3 ml a day, Mexidol, 0.01% of T-activin solution 1-1.2 ml intramusculary, ten injections in a day. Thus Mexidol during the first 10 days is administered in the form of 5% solution of 2-3 ml a day intravenously driply, and the next 10 days in tablets in a daily dose of 100-125 mg. Simultaneously with pharmacotherapy within the first 10 days of 1 times a day perform hyperbaric oxygenation with an overpressure of 0.8-1.0 atmosphere at rate of a compression and decompression of 0.1 atmospheres in a minute, the isopressure period makes 40 minutes.

Agent possessing anxiolythic action, on basis of hydrogenated pyrido (4,3-b) indoles (versions), pharmacological agent on its basis and way of its application / 2338533
Application of hydrogenated pyrido (4,3-b) indoles of the formula (1) or formula (2) as an agent possessing anxiolythic action, a pharmacological agent on its basis and a way of treatment and prevention of stresses, psychic tension, neurosises, obsessional pavors and their consequences is offered.

Method for premedicating cardiovascular abnormality patients within the framework of out-patient visit to dentist / 2321335
Method involves estimating patient health state condition based on diagnostic cardiac rhythm variability data as intersystolic interval duration mean square deviation. The diagnostic index being equal to or less than 20 ms, Tophysopam is to be per os introduced at a dose of 50 mg 30 min before surgical intervention. The diagnostic index value being greater than 20 ms and less than 50 ms, Tophysopam is to be introduced at a dose of 25 mg 30 min before surgical intervention.

Method for treating asthenic disorders due to applying "halavit" preparation / 2319485
Therapeutic scheme in patients that use nootropic preparations should be supplemented with immunomodulator Halavit by a course. It is necessary to carry out 15 intramuscular injections per 100 mg. Such therapy enables to raise the impact of Halavit to higher power at treating asthenic disorders with nootropic preparations and obtain immunomodulating and smooth anxiolytic effect. That leads to improved tolerance of antiasthenic therapy and more qualitative and quicker social adaptation in such patients.

Pharmaceutical composition comprising oxoplatin, its salts and derivatives / 2369396
Invention refers to pharmaceutical set of cancerous disease treatment and prevention. The composition comprises cisdiammoniumdichlor-trans-dihydroxoplatinum (IV), in particular its salts, physically separated from the carrier selected from the group comprising tablet, capsule, coated pill, suppository, ointment, cream, solution for injection where the carrier is combined with cisdiammonium-dichlor-trans-dihydroxoplatinum (IV) immediately prior to use. The invention also refers to pharmaceutical composition obtained from the claimed set.